Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Magic mushroom compound shows promise for suicidal depression

NCT ID NCT05220410

First seen Jan 09, 2026 · Last updated May 23, 2026 · Updated 22 times

Summary

This study tested a single 25mg dose of psilocybin (the active ingredient in magic mushrooms) in 20 adults with depression that didn't respond to standard treatments and who also had ongoing suicidal thoughts. The goal was to see if the drug is safe and tolerable when given in a supportive setting. Researchers measured changes in suicidal thinking and depression severity using standard rating scales.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SUICIDAL IDEATION are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Sheppard Pratt Health System

    Baltimore, Maryland, 21204, United States

Conditions

Explore the condition pages connected to this study.